Singapore's HSA to vet Sinovac vaccine before public roll-out
Singapore
A CORONAVIRUS vaccine developed by China's Sinovac Biotech will have to go through regulatory scrutiny and authorisation by Singapore's Health Sciences Authority (HSA) before it can be rolled out to the public, Health Minister Gan Kim Yong said on Wednesday.
This update follows the release of data on a Brazilian trial on Tuesday, which showed that the Sinovac vaccine was just 50.4 per cent effective at preventing symptomatic infections. This barely meets the threshold for regulatory approval and is well below the rate announced last week.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
International
US firms announce fewer new hires in April: Challenger report
Hong Kong growth beats forecast as recovery gains traction
If inflation continues to build, the Fed won’t be able to maintain neutral stance for long
Thailand to increase daily minimum wage to 400 baht in Oct
UK set for weak growth and highest inflation in G7, OECD says
German manufacturing downturn eases in April, PMI survey shows